Renalytix AI Stock Forecast, Price & News

+0.48 (+1.60 %)
(As of 08/2/2021 11:11 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume418 shs
Average Volume116,238 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RNLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix AI and its competitors with MarketBeat's FREE daily newsletter.

Renalytix AI logo

About Renalytix AI

Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.07 out of 5 stars

Computer And Technology Sector

999th out of 1,646 stocks

Medical Laboratories Industry

29th out of 41 stocks

Analyst Opinion: 1.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Renalytix AI (NASDAQ:RNLX) Frequently Asked Questions

Is Renalytix AI a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Renalytix AI in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Renalytix AI stock.
View analyst ratings for Renalytix AI
or view top-rated stocks.

What stocks does MarketBeat like better than Renalytix AI?

Wall Street analysts have given Renalytix AI a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Renalytix AI wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Renalytix AI's earnings last quarter?

Renalytix AI plc (NASDAQ:RNLX) issued its quarterly earnings results on Tuesday, June, 15th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.03. The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $0.61 million.
View Renalytix AI's earnings history

What price target have analysts set for RNLX?

4 brokerages have issued 1-year target prices for Renalytix AI's stock. Their forecasts range from $22.00 to $38.00. On average, they expect Renalytix AI's stock price to reach $30.00 in the next twelve months. This suggests that the stock has a possible downside of 1.7%.
View analysts' price targets for Renalytix AI
or view top-rated stocks among Wall Street analysts.

Who are Renalytix AI's key executives?

Renalytix AI's management team includes the following people:
  • Mr. James R. McCullough M.B.A., CEO & Exec. Director (Age 53, Pay $487.72k)
  • Mr. Fergus Fleming, CTO & Exec. Director (Age 54, Pay $339.95k)
  • Mr. Thomas H. McLain, Pres (Age 62)
  • Mr. Oliver James Sterling III, Chief Financial Officer
  • Ms. Andria Parks-Herrera, VP of Marketing
  • Dr. Sally Bowden, Head of Regulatory Affairs & CBO (Age 51)
  • Mr. Baljit Singh, Head of Clinical Operations
  • Dr. Michael J. Donovan, Chief Medical Officer (Age 66)
  • Salim Hamir, Company Sec.

Who are some of Renalytix AI's key competitors?

What other stocks do shareholders of Renalytix AI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix AI investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

When did Renalytix AI IPO?

(RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO.

What is Renalytix AI's stock symbol?

Renalytix AI trades on the NASDAQ under the ticker symbol "RNLX."

Who are Renalytix AI's major shareholders?

Renalytix AI's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.33%).

Which major investors are buying Renalytix AI stock?

RNLX stock was bought by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd..

How do I buy shares of Renalytix AI?

Shares of RNLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Renalytix AI's stock price today?

One share of RNLX stock can currently be purchased for approximately $30.53.

How much money does Renalytix AI make?

Renalytix AI has a market capitalization of $1.10 billion. The company earns $-9,840,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Renalytix AI have?

Renalytix AI employs 8 workers across the globe.

What is Renalytix AI's official website?

The official website for Renalytix AI is

Where are Renalytix AI's headquarters?

Renalytix AI is headquartered at AVON HOUSE 19 STANWELL ROAD PENARTH, CARDITH X0, CF64 2EZ.

How can I contact Renalytix AI?

Renalytix AI's mailing address is AVON HOUSE 19 STANWELL ROAD PENARTH, CARDITH X0, CF64 2EZ. The company can be reached via phone at 44-20-3139-2910 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.